| Literature DB >> 33149480 |
Deepak N Singh1, Kumar Chandan Srivastava2, Aparna D Potsangbam3, Deepti Shrivastava4, Doddabasavaiah Basavapur Nandini3, Wahengbam T Singh5, Koijam S Singh1.
Abstract
BACKGROUND ANDEntities:
Keywords: Immunohistochemistry staining; inducible nitric oxide synthase; nitric oxide synthase; oral cancer; oral premalignant
Year: 2020 PMID: 33149480 PMCID: PMC7595486 DOI: 10.4103/jpbs.JPBS_96_20
Source DB: PubMed Journal: J Pharm Bioallied Sci ISSN: 0975-7406
Frequency distribution table showing descriptive statistical analysis of baseline parameters of study groups
| S. no. | Variable | Study group | |||
|---|---|---|---|---|---|
| Group A | Group B | Group C | |||
| 1. | Sample size | 30 | 30 | 30 | |
| Variables related to biographic data––expressed as number (%) except age | |||||
| 2. | Age (expressed as mean ± SD) | 38.97 ± 9.694 | 43.80 ± 11.124 | 62.07 ± 10.184 | |
| 3. | Gender | Female | 7 (23.3) | 8 (26.7) | 12 (40) |
| Male | 23 (76.7) | 22 (73.3) | 18 (60) | ||
| Variables related to tobacco habit––(expressed as mean ± SD) | |||||
| 4. | Duration of habit | Not applicable | 19.50 ± 10.009 | 8.07 ± 3.483 | |
| 5. | Frequency of habit | Not applicable | 8.07 ± 3.483 | 8.40 ± 3.519 | |
| Clinical parameters––expressed as number (%) | |||||
| 6. | Site of lesion | Buccal mucosa | 18 (60) | 6 (20) | |
| Alveolus | 4 (13.3) | 8 (26.6) | |||
| Vestibule | 5 (16.6) | 12 (40) | |||
| Tongue | 3 (10) | 4 (13.3) | |||
SD = standard deviation
Comparative evaluation of inducible nitric oxide synthase levels among the study groups
| S. no. | Study group | Number of cases | No. (%) of cases showing positive for iNOS | |
|---|---|---|---|---|
| 1. | Group A | 30 | 0 | |
| 2. | Group B | 30 | 22 (73.33) | 0.000¶ |
| 3. | Group C | 30 | 25 (83.3) |
iNOS = inducible nitric oxide synthase
¶P < 0.001
Frequency distribution table showing comparative and correlation analysis of inducible nitric oxide synthase expression among different clinicopathological types of oral leukoplakia
| S. no. | Variable | Category | Number of cases | No. (%) of cases showing positive for iNOS expression | ||
|---|---|---|---|---|---|---|
| 1. | Clinical stages (OLEP staging) | Stage I | 6 (20.0) | 3 (50) | 0.015* | |
| Stage II | 8 (26.7) | 6 (75) | 0.001† | |||
| Stage III | 4 (13.3) | 3 (75) | (0.592) | |||
| Stage IV | 12 (40.0) | 10 (83.33) | ||||
| 2. | Histopathological grades (dysplasia) | Mild | 9 (30.0) | 6 (66.6) | 0.008† | 0.001† |
| Moderate | 10 (33.3) | 7 (70) | (0.580) | |||
| Severe | 11 (36.7) | 9 (81.81) |
OLEP = oral leukoplakia staging, iNOS = inducible nitric oxide synthase
*P < 0.05 and †P < 0.01
Frequency distribution table showing comparative and correlation analysis of inducible nitric oxide synthase expression among different clinicopathological types of oral squamous cell carcinoma
| S. no. | Variable | Category | Number of cases | No. (%) of cases showing positive for iNOS expression | ||
|---|---|---|---|---|---|---|
| 1. | Clinical stages (TNM staging) | Stage I | 3 (10.0) | 1 (33.3) | ||
| Stage II | 6 (20.0) | 5 (83.3) | 0.0061† | 0.000¶ | ||
| Stage III | 8 (26.7) | 7 (87.5) | (0.638) | |||
| Stage IV | 13 (43.3) | 12 (92.30) | ||||
| 2. | Histopathological grades (level of differentiation) | Well | 4 (13.3) | 3 (75) | 0.000¶ | |
| Moderate | 12 (40.0) | 9 (75) | 0.0051† | (0.609) | ||
| Poorly | 14 (46.7) | 13 (92.85) |
TNM = tumor, node, and metastasis staging, iNOS = inducible nitric oxide synthase
†P < 0.01 and ¶P < 0.001
Figure 1(A) Well-differentiated OSCC showing inducible nitric oxide synthase (iNOS) staining (×40 magnification). (B) Moderately well-differentiated OSCC showing iNOS staining (×40 magnification). (C) Poorly differentiated OSCC showing iNOS staining (×40 magnification)
Figure 2(A) Moderate dysplasia showing inducible nitric oxide synthase (iNOS) staining (×10 magnification). (B) Severe dysplasia showing iNOS staining (×10 magnification)
Comparative and correlation analysis of inducible nitric oxide synthase expression among the merged clinical stages of oral leukoplakia and oral squamous cell carcinoma
| S. no. | Clinical stages | Number of cases (%) | ||
|---|---|---|---|---|
| 1. | Low risk (Stages I + II) | 14 (46.6) | 0.005† (0.500) | |
| High risk (Stages III + IV) | 16 (53.3) | 0.007† | ||
| 2. | Early OSCC (Stages I + II) | 9 (30) | 0.001† (0.592) | |
| Advanced OSCC (Stages III + IV) | 21 (70) | 0.001† |
OSCC = oral squamous cell carcinoma
†P < 0.01